TGFB1 and cancer: The mechanisms underlying this TGF-β mediated inhibition on immune interventions have not been fully defined, but TGF-β has been shown to suppress type 1 and 2 IFN signaling, as well as adaptive immune responses54–56, and TGF-β inhibitors in combination with PD-1-blockade are in clinical trials of cancer patients.